These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses. Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547 [TBL] [Abstract][Full Text] [Related]
25. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. Kirn DH; Wang Y; Le Boeuf F; Bell J; Thorne SH PLoS Med; 2007 Dec; 4(12):e353. PubMed ID: 18162040 [TBL] [Abstract][Full Text] [Related]
26. Oncolytic viruses-modulated immunogenic cell death, apoptosis and autophagy linking to virotherapy and cancer immune response. Wu YY; Sun TK; Chen MS; Munir M; Liu HJ Front Cell Infect Microbiol; 2023; 13():1142172. PubMed ID: 37009515 [TBL] [Abstract][Full Text] [Related]
27. Oncolytic virus therapy for prostate cancer. Fukuhara H; Homma Y; Todo T Int J Urol; 2010 Jan; 17(1):20-30. PubMed ID: 19832925 [TBL] [Abstract][Full Text] [Related]
28. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies. Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184 [TBL] [Abstract][Full Text] [Related]
29. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes. Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145 [TBL] [Abstract][Full Text] [Related]
30. Modification of mammalian reoviruses for use as oncolytic agents. Van Den Wollenberg DJ; Van Den Hengel SK; Dautzenberg IJ; Kranenburg O; Hoeben RC Expert Opin Biol Ther; 2009 Dec; 9(12):1509-20. PubMed ID: 19916732 [TBL] [Abstract][Full Text] [Related]
31. Oncolytic virus therapy in Japan: progress in clinical trials and future perspectives. Taguchi S; Fukuhara H; Todo T Jpn J Clin Oncol; 2019 Mar; 49(3):201-209. PubMed ID: 30462296 [TBL] [Abstract][Full Text] [Related]
32. Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. Hamid O; Hoffner B; Gasal E; Hong J; Carvajal RD Cancer Immunol Immunother; 2017 Oct; 66(10):1249-1264. PubMed ID: 28712033 [TBL] [Abstract][Full Text] [Related]
35. Unlocking the potential of dimethyl fumarate: enhancing oncolytic HSV-1 efficacy for wider cancer applications. Alwithenani A; Taha Z; Thomson M; Chen A; Wong B; Arulanandam R; Diallo JS Front Immunol; 2023; 14():1332929. PubMed ID: 38169670 [TBL] [Abstract][Full Text] [Related]
37. Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors. Leoni V; Petrovic B; Gianni T; Gatta V; Campadelli-Fiume G J Virol; 2018 Mar; 92(6):. PubMed ID: 29263255 [TBL] [Abstract][Full Text] [Related]
38. Rational selection of an ideal oncolytic virus to address current limitations in clinical translation. Basu R; Moles CM Int Rev Cell Mol Biol; 2023; 379():241-261. PubMed ID: 37541726 [TBL] [Abstract][Full Text] [Related]